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Streptococcus pneumoniae and  Neisseria meningitidis
have very similar mechanisms of resistance to penicillin G.
Although penicillin resistance is now common in S. pneumoni-
ae, it is still rare in N. meningitidis. Using a mathematical model,
we studied determinants of this difference and attempted to
anticipate trends in meningococcal resistance to penicillin G.
The model predicted that pneumococcal resistance in a popula-
tion similar to that of France might emerge after 20 years of
widespread use of β-lactam antibiotics; this period may vary
from 10 to 30 years. The distribution of resistance levels
became bimodal with time, a pattern that has been observed
worldwide. The model suggests that simple differences in the
natural history of colonization, interhuman contact, and expo-
sure to β-lactam antibiotics explain major differences in the epi-
demiology of resistance of S. pneumoniae and N. meningitidis. 
S
treptococcus pneumoniae and Neisseria meningitidis have
very similar mechanisms of resistance to penicillin G, which
are mediated by the decreased affinity of penicillin-binding
proteins (PBPs) (1–3). However, the epidemiology of resis-
tance of these two bacteria exhibit very different patterns.
S. pneumoniae strains with decreased susceptibility have
been found frequently over the last decade, and most of them
now have a penicillin G MIC greater than 2 µg/mL (4,5). By
contrast, for N. meningitidis, reports of high levels of resistance
remain anecdotal, even though decreased susceptibility has
become more frequent (6).
Pneumococcal resistance has already given rise to therapeu-
tic problems (7). Because meningococcal infections are highly
lethal, meningococcal resistance is a major concern. Therefore,
better understanding of S. pneumoniae resistance selection and
establishing whether meningococcal resistance could increase
are important.
In both S. pneumoniae and N. meningitidis, humans are the
only reservoir, and asymptomatic colonization is frequent.
However, the natural history of colonization differs in these
two bacterial species. The average colonization duration of S.
pneumoniae is approximately 2 to 3 months (8), whereas dura-
tion is approximately 10 months for N. meningitidis (9).
Asymptomatic carriage of S. pneumoniae peaks during the first
2 years of life and then gradually declines (10). By contrast,
carriage of N. meningitidis peaks in young adults (9), which
implies a difference in antibiotic exposure and therefore in the
selection pressure borne by these bacteria, as young children
are treated more frequently than young adults.
Mathematical models can be used to explain how these fac-
tors interact in the selection of resistant strains and lead to dif-
ferent trends. Models of transmission have been developed to
examine how antibiotic use affects the colonization rate of
resistant commensal bacteria in human populations (11), to
examine treatment protocols for resistance prevention (12), and
to predict future trends (13). However, these models are based
on a priori hypotheses which, in general, assume that the
impact of antibiotic exposure does not differ according to the
mechanism of resistance and do not consider the particular nat-
ural history of the colonization of the bacterial species.
We describe a mathematical model of the emergence and
diffusion of bacterial resistance in the community. This model
is specific to the mechanism of resistance to penicillin G com-
mon to S. pneumoniae and N. meningitidis and mediated by the
decrease in affinity of their PBPs. The model also takes into
account the natural histories of colonization of the two bacteria. 
Using this model, we first explored the case of S. pneumo-
niae and validated our predictions by using independently
obtained epidemiologic data. Next, we studied N. meningitidis
to anticipate its trends in penicillin G–resistance selection
according to antibiotic exposure.
Materials and Methods
Microbiologic Background and Hypotheses
β-lactam antibiotics, such as penicillin G, bind to PBPs in
the bacterial cell wall. In both S. pneumoniae and N. meningi-
tidis, the main mechanism of penicillin G resistance is mediat-
ed by the alteration of these penicillin target enzymes. The
genetic events leading to reduced affinity for penicillin G are
1) point mutations that confer slight increases in resistance and
2) acquisition by transformation from other commensal species
of the pharynx of intragenic sequences, which leads to the syn-
thesis of mosaic PBPs and confers higher levels of resistance
(14-16).
By convention, the decrease in susceptibility to penicillin G
is defined by an MIC >0.1 µg/mL and resistance by an MIC >2
µg/mL (5). In the laboratory, the MIC is determined by succes-
sive dilutions and presented on a log2 scale. However, genetic
events may lead to a difference of less than a log2 unity
between two MICs; for example, an increase from 0.04 to 0.06
µg/mL was reported by Hakenbeck et al. (17).
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rized that each bacterial generation provided an opportunity for
an increase in resistance. More precisely, we randomly select-
ed for each new generation an increase in the bacterial MIC,
defined as d, according to the seminormal law:
f∆(d) =                 .  
With this formulation, a high probability exists that either
no genetic event occurs or that such an event will only convey
a small increase in MIC, although an increase to any resistance
level as a result of one genetic event remains possible. In par-
ticular, a detectable genetic event, that is, an event conveying
an increase in the MIC of more than one log2 unity, will occur
with a frequency of 10-7, which is consistent with previous in
vitro observations (18).
Bacteria colonize human hosts in large quantities.
Therefore, even though the occurrence of genetic events
remains possible for each bacterium, competition makes it
unlikely that a host’s bacterial population will suddenly be
replaced by genetically altered strains. However, in the pres-
ence of antibiotic treatment, selective killing of the susceptible
bacterial population may allow replacement by a less suscepti-
ble population. We therefore assumed that genetic events lead-
ing to effective bacterial replacement were only possible in
treated persons. We represented the entire bacterial population
of a colonized host by one MIC. 
Model Description
To reproduce the selection and spread of resistant bacteria in
the community through interhuman transmission, we divided
the human population under study into several groups or “com-
partments” (Figure 1). Each compartment was composed of
persons with the same characteristics regarding colonization
and antibiotic treatment. The colonized compartments were
split into several subcompartments according to MIC. 
Uncolonized persons are colonized after an infectious con-
tact with colonized persons at rate β. In the absence of antibi-
otic treatment, the persons are then naturally decolonized after
a time 1/λ, regardless of MIC. This period, called the duration
of carriage, is followed by a refractory period of duration 1/θ,
during which these persons cannot be colonized again. 
With antibiotic treatment, bacterial colonization is cleared
with a probability σ. In persons in whom colonization is not
eliminated, bacteria with a mutation towards a higher MIC may
replace the original strains. 
Finally, progression from the untreated category to the treat-
ed category occurs at the start of an antimicrobial treatment,
which takes place with a frequency α, and the return to the
untreated category occurs when the treatment comes to an end,
after an average duration of 1/γ.
Parameters
The mean duration of carriage is reportedly 2.2 months for
S. pneumoniae and 10 months for N. meningitidis (8,9).
Although temporary systemic immunization has occurred after
colonization by these bacteria (19), the exact duration of this
refractory phase is not clear. We chose a duration of 2 weeks
and investigated the range from 4 days to 2 months.
In studies of treatment patterns in France, the average dura-
tion of antibiotic treatment was 8 days (20,21) and the frequen-
cy of treatment changed with age. Young children may be treat-
ed several times a year with penicillin G, while healthy adults
are only treated once every 4 to 5 years on average. The colo-
nization frequency also changes with age, corresponding to col-
onization peaks in children for S. pneumoniae and in young
adults for N. meningitidis. In our model, the population was not
structured by age, but we wanted to reflect these hetero-
geneities. We therefore calculated effective treatment frequen-
cies by weighting observed frequencies of treatment with prob-
abilities of colonization according to age, which led us to study
the effects of one treatment every 2 years for S. pneumoniae
and one treatment every 3 years for N. meningitidis.  
We assumed that, with treatment, all bacteria were submit-
ted to the same concentration of antibiotics; therefore, we con-
sidered the probability of decolonization after treatment as a
function of MIC only. Acommonly used model for the effect of
an antibiotic on bacteria with a given MIC according to drug
concentration is the saturating model (13). By analogy, we
expressed the effect of a given antibiotic concentration in terms
of the probability of nondecolonization as a function of the
MIC m, by
σ(m) = .
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Figure 1. Structure of the model emergence and transmission of peni-
cillin G resistance in Streptococcus pneumoniae and Neisseria menin-
gitidis.We chose a constant infectious contact rate β in the absence
of treatment. We adjusted the value of β so that the predicted
proportion of carriers matched the observed values of 45% in
the case of S. pneumoniae (10) and of 10% in the case of N.
meningitidis (9). This gave β=0.23 weeks-1 person-1 for S. pneu-
moniae and  β=0.026 weeks-1  person-1 for  N. meningitidis.
However, we assumed that a treated person had a better chance
of being colonized after a contact than an untreated person if
the bacteria involved had a high MIC and that colonization was
less probable with susceptible bacteria. We also adopted the
following sigmoidal function of the MIC m for the contact rate
in the presence of treatment
β'(m) = .
The values of the model’s parameters are specified in Table
1. Model simulations are described in the Appendix.
S. pneumoniae Historical Data in France
To validate the predictions of the model for changes in
resistance, we used data on S. pneumoniae reported to the
French National Reference Center (NRC) for pneumococci
(22). In short, 40–50 centers throughout France collected and
sent S. pneumoniae strains to the NRC. Each year approxi-
mately 2,000 strains were typed and evaluated for susceptibil-
ity to various antibiotics. We used data from 1987 to 1997 and
looked at changes in the distribution of penicillin G MICs over
time.
Results
Predictions for S. pneumoniae
Emergence
By applying the model to a population in which all the pneu-
mococci were initially susceptible to penicillin G (MIC < 0.06
µg/mL), we determined the time of emergence of the first
strains with decreased susceptibility (MIC = 0.125, 0.25, 0.5,
and 1 µg/mL), as well as the first resistant strains (MIC = 2
µg/mL) and highly resistant strains (MIC = 4 µg/mL). The
model also provided information on the variability of these
emergence times (Figure 2a). In particular, the model predicted
the emergence of high resistance levels (MIC >2 µg/mL) after
approximately 20 years of antibiotic use. 
At low resistance levels, the mean time to emergence
depended strongly on MIC. At higher levels (MIC >1 µg/mL),
however, it reached a plateau, as the lag between the emergence
of two successive levels decreased. The variability of these
estimated times to emergence was marked, ranging from 10 to
30 years when starting from the same situation for the emer-
gence of a strain with MIC 2 µg/mL.
We sought to clarify the relationship between the time
required for a strain with a given MIC to be selected and the
time in which the strain spreads to a large portion of the popu-
lation. We determined the time at which 20% of the colonized
population would be carrying strains with MIC levels ranging
from >0.125 to 4 µg/mL (Figure 2a). This time appeared to
depend very little on the MIC, even at low resistance levels, in
contrast to the time to emergence, which began with a large
increase with MIC. However, both times displayed comparable
variability (data not shown).
Transmission
We applied the model to a population in which resistance
had already emerged, so that most pneumococcal strains were
still susceptible to penicillin G, but some strains had high
MICs. This pattern corresponds to the situation in France
around 1987 (22). Figure 2b illustrates the model’s predictions
for the evolution with time of the distribution pneumococcal
strains according to their MIC. In particular, after a few years,
this distribution acquired a bimodal shape, with a peak for sus-
ceptible bacteria and another for resistant bacteria. 
Figure 2c shows the evolution of pneumococcal resistance
to penicillin G during 1987 to 1997, as observed by the French
National Reference Center for Pneumococci (4). In 1997, the
distribution of resistance levels, which was initially unimodal,
exhibited a bimodal shape, with a peak for susceptible bacteria
and another for resistant bacteria. This is consistent with the
model’s predictions (Figure 2b). 
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Table 1. Model parameters and their values (8,21) 
Parameters (at MIC m)  Pneumococci  Meningococci 
Treatment duration  1/γ  8 d  8 d 
Weighted frequency of treatment  α  1 / 2 y  1 / 3 y 
Refractory phase duration  1/θ  2 wk  2 wk 
Carriage duration  1/λ  2.2 mo  10 mo 
Time before antibiotic action  1/ν  4 d  4 d 
Contact rate (absence of treatment)  β  0.23 wk
-1person
-1  0.026 wk
-1person
-1 
Contact rate (presence of treatment)  β´(m) 
3
3
5 . 0
. 46 . 0
m
m
+
 
3
3
5 . 0
. 052 . 0
m
m
+
 
Nondecolonization probability after treatment  σ (m)    
3
3
05 . 0 m
m
+
 
3
3
05 . 0 m
m
+
 
MIC increase after a genetic event  F (m)  Randomly selected from a seminormal law Predictions for N. meningitidis
Starting with approximately 30% of strains with reduced
susceptibility to penicillin G, we used the same model to pre-
dict changes in the distribution of meningococcal MIC levels.
Meningococcal resistance seemed to increase in the same way
as pneumococcal resistance and also exhibited a bimodal distri-
bution of MIC levels (Figure 3a). However, change was slow-
er in this case because of reduced frequency of treatment in the
population concerned and reduced transmissibility.
We studied a situation in which intervention would reduce
the frequency of treatment by half (Figure 3b). Even under this
reduced antibiotic pressure, high levels of resistance eventual-
ly appeared but with a delay of approximately 15 years.
Discussion
In this study, we developed a mathematical model of the
emergence and spread of penicillin G–resistant bacteria in the
community that was specific to a resistance mechanism com-
mon to S. pneumoniae and N. meningitidis. The model shows
that differences in the natural history of colonization, contact,
and treatment rates can account for the differences in the epi-
demiology of the resistance of these two bacterial species.
Figure 2a highlights the difference between the isolation of
a strain of reduced susceptibility and its spread in the commu-
nity. A strain with a low resistance level does not have enough
selective advantage to assure its persistence in the population.
Therefore, this strain will probably disappear before a genetic
event causes an increase of its MIC. For example, the large dif-
ference between the mean times of emergence of a strain with
an MIC of 0.125 µg/mLand a strain with an MIC of 0.5 µg/mL
corresponds to several successive processes of the emergence
and elimination of strains with an MIC <0.5 µg/mL. On the
contrary, at resistance levels greater than 1 µg/mL, the emer-
gence of a strain frequently leads to its spread in the communi-
ty and the prompt emergence of strains with higher resistance
levels. After the first emergence of such a strain, it may take a
few years to spread to 20% of the colonized population with an
MIC of 2 µg/mL.
One major finding was the variability of the time to selec-
tion of bacteria with a given MIC. For example, starting from
an all-susceptible bacterial population, a strain of S. pneumoni-
ae with an MIC >2 µg/mLcould be selected as soon as 10 years
after the start of antibiotic use but also as late as 30 years later.
Furthermore, this finding suggests that the absence of emer-
gence after 30 years is unlikely, which is consistent with obser-
vations (e.g., the first penicillin G-resistant S. pneumoniae
strains worldwide appeared around 1970, while penicillin G
had been commonly used since 1950) (22).
The model predicted an increase in pneumococcal resist-
ance leading to bimodality of MIC levels. This increase was
also noted in the French data (4), as well as in other studies
(23–25). Good agreement exists between the predicted and
observed values (Figure 2).
A prediction of the model is that resistance of N. meningi-
tidis will probably increase, although slowly, even if antibiotic
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Figure 2. (a) Time to emergence of the first Streptococcus pneumoniae
with a given MIC (full line) and time required for 20% of the bacterial
population to reach this MIC (dotted line), starting from an all-suscepti-
ble pneumococcal population. Error bars correspond to stochastic vari-
ations in the model simulations (10th and 90th percentiles based on 100
simulations). (b) Simulated and (c) observed changes with time since
1987 in the distribution of resistance levels in the pneumococcal popu-
lation in France.  Observed data are taken from the Centre National de
Référence des Pneumocoques (4).
a
b
cpressure were reduced (Figure 3b). Several parameters chosen
were derived from direct measures in the community or in
vitro, but others required indirect evaluations. We performed a
sensitivity analysis using the Latin Hypercube sampling tech-
nique (26). This analysis showed that for predicting the per-
centage of resistant bacteria, the frequency of treatment was the
most critical parameter (positively linked, Table 2), followed
by the carriage duration (negatively linked), the treatment dura-
tion (positively linked), and the contact rate (positively linked).
Also, a reasonable range of values for the duration of the
refractory phase has little effect on model outcomes. Likewise,
the choice of the constants and of the exponent of m in the
probability of nondecolonization after treatment σ(m) and in
the contact rate β´(m) do not have critical effects. 
The following simplifications were adopted in the model.
First, rather than considering explicitly the changes in treat-
ment frequencies with age, we used a treatment frequency aver-
aged over age. Second, we only considered resistance caused
by decreased affinity to PBPs, although other mechanisms may
contribute to increase resistance (27,28), and we used the same
mathematical description for all genetic events leading to
resistance, i.e., point mutations and genetic material transfer
(29) because this is supported by experimental observations
(30). The very shape of the distribution used to model these
increases in MIC did not alter the predictions, because selection
of resistant strains in the community arose primarily by inter-
human transmission. Finally, we did not include a fitness cost
for resistant S. pneumoniae or N. meningitidis, although it has
been found in other bacterial species (31), with the conse-
quence that resistance progression may eventually spread faster
than predicted here.
Insofar as our model takes into account both the natural his-
tory of colonization and the resistance mechanism of the bacte-
ria considered (Appendix), the model is more realistic than
general models such as those previously developed to obtain a
general view of resistance (32). However, several aspects of the
model could still be more complex to address specific prob-
lems, even though a certain level of simplification remains
compulsory in a model. For instance, several serotypes of both
S. pneumoniae and N. meningitidis cocirculate in the commu-
nity. Differences exist in the transmissibility and duration of
carriage of these bacteria, depending on their serotype; these
differences could impact on resistance selection (9). Taking
two or more bacterial serogroups into account instead of one
would therefore be worth considering.
Moreover, we considered treatment with β-lactam antibi-
otics, whereas several antibiotics are widely used in the com-
munity. Penicillin G–resistant S. pneumoniae tends to be
increasingly multidrug resistant (4). Taking this resistance into
account may increase the impact of antibiotic exposure and
therefore accelerate the changes predicted by the model. The
general framework we described could be adapted to the study
of other bacteria, provided the parameter values were chosen to
reflect the natural history of colonization and the way in which
the treatment failure probability σ (m) depends on the MIC m.
Finally, recently developed polysaccharide-protein conju-
gate vaccines have been shown to protect persons against
symptomatic and asymptomatic colonization by S. pneumoniae
or N. meningitidis (33,34). This protection is specific to the
serotypes included in the vaccines. Our model could evaluate
the impact of the use of such vaccines. Strategies for vaccina-
tion against S. pneumoniae or N. meningitidis may differ wide-
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Figure 3. Simulated changes with time in the distribution of resistance
levels in the meningococcal population, starting from a situation close
to that of France in 2001, under (a) constant antibiotic treatment condi-
tions (1 treatment/3 y) and (b) a frequency of treatment reduced by half
(1 treatment/6 y).
a
b
Table 2. Sensitivity analysis of the model  
Parameters  PRCC 
Weighted frequency of treatment  α  0.981651 
(Carriage duration) 
–1  λ  0.672063 
(Treatment duration) 
–1  γ  -0.472343 
Contact rate (absence of treatment)  β  0.392559 
aKey factors that increase (Partial Rank Correlation Coefficient [PRCC]>0) or decrease 
(PRCC<0) the prevalence of penicillin-resistant Streptococcus pneumoniae after 10 
years, starting from an all-susceptible population. ly; as vaccination for all children is recommended for S. pneu-
moniae (35), whereas targeted vaccination campaigns are more
often conducted for N. meningitidis (36,37). 
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Appendix
Numerical Treatment of the Model
Classically, compartmental models are studied through a set of dif-
ferential equations, which allows the computing of deterministic pre-
dictions. However, it is also possible to consider the transitions
between compartments as random phenomena, to which a probability
can be associated. This latter approach, called stochastic, offers the
advantage of being more realistic than the classical deterministic ver-
sion, as it takes into account the biological variability of the system
and enables its measuring. We used both a deterministic and a stochas-
tic version of the model in this study. 
Deterministic Model
The equations used are as follows
where at time t, Unp(t) is the proportion of uncolonized untreated hosts
in the population, Uref(t) the proportion of untreated hosts in a refrac-
tory phase, Vnp(t) the proportion of uncolonized treated hosts, Up(m,t)
the density of untreated hosts colonized with bacteria with MIC m, and
Vp(m,t) the density of treated hosts colonized with bacteria with MIC
m (38).
Stochastic Model
Interested readers may contact the first author for technical details
about the simulations that were performed by using Gillespie’s Direct
Method (39).
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